> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-31/
- Published: 2020-11-08T12:00:00.000Z
- Updated: 2026-09-14T16:35:33.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140505

**Context Therapeutics**, a biopharma company dedicated to developing new medicines for patients with hormone responsive cancers, announced that it has acquired from **Arno Therapeutics** the worldwide rights to Apristor (onapristone XR). Onapristone has been studied in two Phase 2 metastatic breast cancer clinical trials. In these trials, meaningful clinical benefit and response rates were seen in 120 metastatic breast cancer patients, 101 of whom were actively progressing on Tamoxifen before Onapristone treatment initiation, according to the companies.

**ACM Global Laboratories** has acquired Philadelphia-based **DrugScan, Inc.,** a toxicology laboratory testing company. ACM says that while toxicology testing demand grows in the wake of the national opioid epidemic, health systems nationally will need to partner with innovative companies like DrugScan to help providers manage and treat patients with complex medication needs. Details of the transaction were not disclosed.

**Guerbet** has entered into an agreement under which it will acquire Israeli company **Accurate Medical Therapeutics**, which specializes in the development of microcatheters used in interventional radiology. Accurate has developed a range of microcatheters for embolization procedures of tumors and vascular aneurysms. These products are currently being registered with the U.S. and European health authorities.